Open AccessA Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
Author(s) -
Yirepanjaing Ailiyaer,
Xiuxiu Wang,
Yan Zhang,
Caiyu Li,
Tao Li,
Qian Qi,
Yu Liu
Publication year - 2018
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000486134
Subject(s) - medicine , bronchiectasis , exacerbation , amikacin , prospective cohort study , intensive care medicine , asthma exacerbations , anesthesia , emergency medicine , asthma , lung , antibiotics , microbiology and biotechnology , biology
Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of nebulized amikacin treatment are unknown.